SuperworthAmylyx Pharmaceuticals AMLX
- Market cap
- $3B
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- one or more of the four quarters through 2026-06-30 missing
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Net margin
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Free cash flow yield
- n/m
- not a meaningful number
Amylyx Pharmaceuticals' trailing earnings are negative, so it has no PE.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $102.7M+29666% | $108.4M+396% | $88.6M+24% | −$1M | $416K−100% | n/a | $0 | $0 | $0 | n/a | n/a | n/a | |
| Cost of revenue | $5.2M+2934% | $9.4M+232% | $5.9M+13% | $8K−100% | $0 | n/a | $0 | $0 | $0 | n/a | n/a | n/a |
| Gross profit | $97.5M+56244% | $99.1M+420% | $82.7M+25% | −$1M | $416K−100% | n/a | $0 | $0 | $0 | n/a | n/a | n/a |
| R&D | $30M+21% | $44.9M+97% | $36.6M+51% | $23.3M−20% | $21.2M−29% | n/a | $22.1M−40% | $27.2M+17% | $19.9M−7% | n/a | $27.6M+25% | $23.8M−13% |
| SG&A | $48.7M+63% | $52.2M+28% | $57.8M+31% | $21.6M−50% | $17.8M−63% | n/a | $15.7M−73% | $15.6M−28% | $16.2M−9% | n/a | $16.2M+3% | $21.9M+40% |
| $18.7M | $1.9M | −$122.1M+5849% | −$76.3M | −$75.7M | n/a | −$37.8M−69% | −$42.9M−44% | −$36M−52% | n/a | −$43.8M+16% | −$45.7M+7% | |
| Pre-tax income | $22.4M | $6.5M | −$118.6M | −$72.7M | −$72.7M | n/a | −$35.9M−70% | −$41.4M−43% | −$34.4M−53% | n/a | n/a | n/a |
| $1.5M | $1.7M+201% | $242K | $0 | $0 | n/a | $0 | $0 | $0 | n/a | n/a | n/a | |
| Net income | $20.9M | $4.7M | −$118.8M | −$72.7M | −$72.7M | −$37.5M | −$35.9M−70% | −$41.4M−43% | −$34.4M−53% | −$33M−12% | −$41.3M+15% | −$43.4M+5% |
| $0.30 | $0.07 | −$1.75 | −$1.07 | −$1.07 | −$0.55 | −$0.42−76% | −$0.46−57% | −$0.37−65% | −$0.30−46% | −$0.37−12% | −$0.39−15% | |
| 69.7M+19% | 69.5M+6% | 67.9M−4% | 68M−3% | 68.1M−2% | 68.6M−1% | 85.7M+26% | 89.1M+31% | 93.3M+37% | 109.8M+60% | 110.6M+29% | 111.2M+25% |
Gross profit: 12 periods, Q3 FY22 to Q3 FY25: not printed by the filing, worked out from its own lines.
EPS, diluted: 5 periods, Q4 FY21 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 4 periods, Q4 FY21 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY23: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest Amylyx Pharmaceuticals' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| AMLXAmylyx Pharmaceuticals | $3B | n/m | 3.9× | n/m | n/m | n/m | |
| NRIXNurix Therapeutics | $2.8B | 11.0× | 10.8× | 3.9× | n/m | 42.0% | |
| OGNOrganon | $3.6B | 17.9× | 5.9× | 0.6× | −2% | 3.4% | |
| LQDALiquidia | $3.8B | 30.7× | 53.6× | 8.5× | n/m | 30.7% | |
| ARQTArcutis Biotherapeutics | $3.9B | 142× | 115× | 8.5× | +76% | 6.1% | |
| PBHPrestige Consumer Healthcare | $2.3B | 13.4× | 15.3× | 2.0× | −1% | 15.6% | |
| INDVIndivior Pharmaceuticals | $4.1B | 12.4× | 20.1× | 3.1× | +13% | 26.7% | |
| HRMYHarmony Biosciences | $2.1B | 11.7× | 13.8× | 2.2× | +24% | 18.9% | |
| ANIPANI Pharmaceuticals | $1.7B | 15.4× | 60.6× | 1.7× | +31% | 11.1% | |
| PAHCPhibro Animal Health | $1.6B | 15.9× | 21.5× | 1.0× | +17% | 6.6% | |
| KNSAKiniksa Pharmaceuticals International | $6B | 79.1× | 85.3× | 7.1× | +59% | 9.6% | |
| Peer median | $3.2B | 15.7× | 20.8× | 2.6× | +21% | 13.3% |
More on Amylyx Pharmaceuticals
Each number over time
- PE ratio
- Price to sales ratio
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .